{"id":128549,"date":"2025-10-17T18:14:08","date_gmt":"2025-10-17T18:14:08","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/128549\/"},"modified":"2025-10-17T18:14:08","modified_gmt":"2025-10-17T18:14:08","slug":"heres-what-trump-said-thats-pressuring-novo-nordisk-and-eli-lilly-stocks","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/128549\/","title":{"rendered":"Here&#8217;s What Trump Said That&#8217;s Pressuring Novo Nordisk and Eli Lilly Stocks"},"content":{"rendered":"<p> Key Takeaways<\/p>\n<ul>\n<li>President Trump said he would lower the prices of popular weight-loss drugs, pressuring shares of drugmakers Novo Nordisk and Eli Lilly Friday.<\/li>\n<li>Centers for Medicare &amp; Medicaid Services head Dr. Mehmet Oz said price negotiations have not finished yet.<\/li>\n<\/ul>\n<p id=\"mntl-sc-block_2-0\" class=\"comp mntl-sc-block finance-sc-block-html mntl-sc-block-html\"> Novo Nordisk (<a href=\"https:\/\/www.investopedia.com\/markets\/quote?tvwidgetsymbol=NVO\" data-component=\"link\" data-source=\"inlineLink\" data-type=\"internalLink\" data-ordinal=\"1\" rel=\"nofollow noopener\" target=\"_blank\">NVO<\/a>) and Eli Lilly (<a href=\"https:\/\/www.investopedia.com\/markets\/quote?tvwidgetsymbol=LLY\" data-component=\"link\" data-source=\"inlineLink\" data-type=\"internalLink\" data-ordinal=\"2\" rel=\"nofollow noopener\" target=\"_blank\">LLY<\/a>) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk\u2019s Ozempic and Eli Lilly\u2019s Zepbound.\n<\/p>\n<p id=\"mntl-sc-block_4-0\" class=\"comp mntl-sc-block finance-sc-block-html mntl-sc-block-html\"> In comments to reporters during a White House event Thursday, Trump said prices could drop to $150 a month from $1,300. When asked which treatment he meant, Trump pointed to Novo Nordisk\u2019s Ozempic, saying prices for weight-loss drugs like it will be &#8220;much lower.&#8221;\n<\/p>\n<p id=\"mntl-sc-block_6-0\" class=\"comp mntl-sc-block finance-sc-block-html mntl-sc-block-html\"> Ozempic\u2019s current list price is $1,000 a month, but Novo Nordisk offers it to consumers buying in cash without insurance for less. Dr. Mehmet Oz, head of the Centers for Medicare &amp; Medicaid Services (CMS), said the CMS has not yet finished negotiating costs with pharmaceutical firms.\u00a0\n<\/p>\n<p id=\"mntl-sc-block_8-0\" class=\"comp mntl-sc-block finance-sc-block-html mntl-sc-block-html\"> Shares of Novo Nordisk were down about 4% in recent trading, while shares of Eli Lilly dropped 3%.\n<\/p>\n<p> Why This Is Significant<\/p>\n<p>President Trump\u2019s recent comments come amid a\u00a0<a href=\"https:\/\/www.investopedia.com\/a-new-way-to-buy-cheaper-meds-might-be-coming-here-s-what-pfizer-and-trump-are-planning-11826616\" data-component=\"link\" data-source=\"inlineLink\" data-type=\"internalLink\" data-ordinal=\"1\" rel=\"nofollow noopener\" target=\"_blank\">broader effort<\/a> by the administration to cut drug prices in the U.S. to align with lower international rates.<\/p>\n<p id=\"mntl-sc-block_11-0\" class=\"comp mntl-sc-block finance-sc-block-html mntl-sc-block-html\"> A Novo Nordisk spokesperson told Investopedia the company has engaged with the Trump administration, and &#8220;will continue to work to find solutions that help people access the medication they need.&#8221;\n<\/p>\n<p id=\"mntl-sc-block_13-0\" class=\"comp mntl-sc-block finance-sc-block-html mntl-sc-block-html\"> U.S.-listed shares of Novo Nordisk have lost more than a third of their value this year as the company faces growing competition in the weight-loss drug market. Shares of Eli Lilly have added about 3%.<\/p>\n","protected":false},"excerpt":{"rendered":"Key Takeaways President Trump said he would lower the prices of popular weight-loss drugs, pressuring shares of drugmakers&hellip;\n","protected":false},"author":2,"featured_media":128550,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[18,135,475,474,19,17],"class_list":{"0":"post-128549","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-eire","9":"tag-health","10":"tag-health-care","11":"tag-healthcare","12":"tag-ie","13":"tag-ireland"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/128549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=128549"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/128549\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/128550"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=128549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=128549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=128549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}